ArticleiScience2026

Safety and immunogenicity of an adjuvant-free peptide vaccine targeting IL-17A: Phase 1 randomized controlled trial.

Satoru Kasahara et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.